Alzheimer’s Blood Tests Enter Clinical Use, Spark Debate on Early Diagnosis

The blood draw looked routine. The questions that followed it did not.

At a family medicine clinic outside St. Louis, a 62-year-old man with mild memory complaints recently watched his physician hover over a new option in the electronic ordering system: a blood test that, with striking accuracy, can detect the brain changes associated with Alzheimer’s disease.

“He wanted to know if his wife, who’s perfectly fine, should get one too,” the doctor recalled. “That’s when you realize this isn’t just another lab.”

After decades of reliance on spinal taps and expensive brain scans, blood tests for Alzheimer’s are moving rapidly into everyday medicine. Built around a powerful biomarker called phosphorylated tau 217, or p‑tau217, they promise quicker, cheaper answers for patients worried about their memory.

Scientists and ethicists say they are also about to test how far society is willing to go to peer into the future of the aging brain.

The Food and Drug Administration has cleared the first Alzheimer’s blood tests for routine clinical use in the United States, including one aimed squarely at primary care doctors.

In May 2025, the agency authorized the Lumipulse G pTau 217/β‑Amyloid 1‑42 Plasma Ratio test from Fujirebio as the first FDA‑cleared blood-based diagnostic to help identify amyloid plaques associated with Alzheimer’s disease. The test is indicated for adults 55 and older who already have cognitive impairment and are being evaluated for possible Alzheimer’s.

Five months later, in October, FDA cleared Roche’s Elecsys pTau181 plasma assay, the first Alzheimer’s-related blood biomarker test specifically labeled for use in primary care. The test is intended to help family doctors rule out Alzheimer’s-related amyloid pathology in symptomatic patients 55 and older, so they can look for other causes of memory problems.

“This test is designed to rule out the presence of amyloid plaques,” Joanne Pike, president and CEO of the Alzheimer’s Association, said when the Roche clearance was announced. “It is not a test that will give an Alzheimer’s disease diagnosis, nor is it a standalone tool for detection.”

At the same time, more sensitive p‑tau217 tests, some capable of flagging changes in people with no outward symptoms, are proliferating through hospital systems and national laboratories under looser rules that govern so‑called laboratory-developed tests.

Together, the tests are driving an inflection point in how and when Alzheimer’s is detected—long before experts agree on how such information should be used.

Alzheimer’s has always been diagnosed late and definitively confirmed only with invasive or costly tools.

The disease, the most common cause of dementia, is defined biologically by sticky amyloid plaques and tangles of tau protein that accumulate in the brain. For years, clinicians wanting to see those hallmarks had two options: amyloid PET scans that can cost thousands of dollars, or lumbar punctures to draw cerebrospinal fluid.

Blood tests aim to change that. They measure tiny amounts of abnormal proteins that spill from the brain into the bloodstream as the disease process unfolds.

Among those markers, p‑tau217 has emerged as the star. Large studies have found that it distinguishes people with biologically defined Alzheimer’s from those without the disease with close to 90% sensitivity and 90% specificity—performance on par with, and in some cases better than, spinal fluid tests.

Recent research goes further. In cognitively normal adults, elevated p‑tau217 levels in midlife can predict amyloid positivity on PET scans and are associated with substantially higher risk of future cognitive decline. In a study published earlier this year, scientists reported that a model based on p‑tau217 and other measures could estimate when initially asymptomatic people would develop memory symptoms, often three to four years in advance.

For drug developers, such abilities are a boon: they allow researchers to find people in the earliest biological stages of disease for clinical trials. For patients and families, they suggest a simple blood draw could soon offer something close to a timetable for their own cognitive decline.

That prospect is exactly what worries many clinicians.

“If you tell a 55‑year‑old that their blood looks like someone on the path to Alzheimer’s, you’re potentially changing their life decades before anything happens,” said Dr. William Hu, a neurologist at Rutgers Robert Wood Johnson Medical School. “Right now, we don’t have clear guidance on whether that helps them—or hurts them.”

Even before FDA cleared the first Alzheimer’s blood tests, the United States had become a major market for lab‑developed assays offered out of single laboratories under federal lab regulations rather than through premarket FDA review.

C2N Diagnostics, a St. Louis company spun out of Washington University, markets PrecivityAD tests that use mass spectrometry to measure p‑tau217 and amyloid ratios in plasma and estimate brain amyloid burden. Labcorp sells an “ATN Profile” that combines amyloid, tau and a marker of neurodegeneration in blood.

In 2023, Quest Diagnostics went further, selling an amyloid Aβ42/40 ratio test directly to adults as young as 18 under the brand AD‑Detect. Consumers could order the $299 blood test online without seeing a doctor and receive a result classed as “higher,” “intermediate” or “lower” risk.

Memory specialists raised alarms. An analysis by the Penn Memory Center in Philadelphia estimated that nearly three in 10 people labeled “high risk” by the test would be false positives, and noted there was little evidence at the time that amyloid blood ratios predicted dementia in healthy adults.

“This test is premature,” Claire Erickson, a neuropsychologist at the center, said when the product was launched. “There is a nearly one‑third false‑positive rate, and there is not a robust process to help people understand what the results mean. That is concerning.”

Under growing criticism, Quest withdrew the direct‑to‑consumer version and later shifted to offering physician‑ordered tests, including the FDA‑cleared Fujirebio assay.

In 2024, FDA moved to tighten oversight of such lab-developed tests, finalizing a rule that will, over several years, require new high‑risk tests for serious conditions to undergo the same premarket review as commercial diagnostics. But most Alzheimer’s blood tests already on the market as of May 6, 2024, were effectively grandfathered in. They must register with FDA and report problems, but they do not need to retroactively prove their accuracy to regulators.

Demand for all these tests is being fueled by grim demographics and modest new drugs.

Roughly 7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2025, according to the Alzheimer’s Association, a toll projected to nearly double by 2060 as the population ages. Health and long‑term care costs for people with dementia reached an estimated $232 billion in 2025, not counting the unpaid labor of family caregivers.

For the first time, there are disease‑modifying drugs on the market that target amyloid plaques. Leqembi, from Eisai and Biogen, gained full FDA approval in 2023, followed by Eli Lilly’s Kisunla in 2024. Both are intravenous monoclonal antibodies for people with very early symptomatic Alzheimer’s—mild cognitive impairment or mild dementia—and both require evidence of amyloid pathology before treatment.

That has made biomarker testing the gatekeeper to therapies that can cost tens of thousands of dollars per year and require frequent infusions and MRI scans to monitor side effects.

At the same time, surveys suggest the public is hungry for early answers. In a 2025 nationwide poll of U.S. adults 45 and older commissioned by the Alzheimer’s Association, 99% said early diagnosis of Alzheimer’s is important. About four in five said they would want to know if they had the disease before symptoms interfered with daily life, and roughly half said they would want to know even before any symptoms appeared. More than 90% said they would want a simple medical test like a blood test for Alzheimer’s if it were available.

Yet sizable minorities also voiced reservations: 44% worried their insurance would not cover needed care if they tested positive, and 41% worried about test accuracy.

Scientists say those worries are not hypothetical.

In February 2025, Hu and colleagues at Rutgers and Emory University published one of the first large studies to examine how p‑tau217 blood tests perform in diverse, real‑world populations. They found that when a single threshold optimized in a mostly White group was applied to Black participants, the test’s sensitivity dropped from about 90% to roughly 74%, and specificity fell from about 81% to around 73%.

“Blood tests for Alzheimer’s are very promising, but they have many caveats,” Hu said. He noted that underlying conditions such as chronic kidney disease or vascular problems can alter biomarker levels, and that some research suggests tau proteins may move differently from cerebrospinal fluid into the blood in different groups.

“Using the same cut point for everyone risks missing the disease in some people and falsely diagnosing it in others,” he said.

Other researchers have warned that obesity, systemic inflammation and other common illnesses can push amyloid or tau levels up or down, complicating interpretation outside of carefully screened study volunteers.

Those issues are particularly acute in communities that already have less access to neurologists and advanced imaging. A false reassurance from a blood test could delay a correct diagnosis; a false positive could send someone down an expensive and stressful path toward confirmatory PET scans and specialist visits they may struggle to obtain.

Beyond accuracy, ethicists and clinicians are concerned about what happens to people who learn they have “preclinical Alzheimer’s disease” based on blood work alone.

In a Viewpoint article published in February in the journal JAMA, researchers called blood-based biomarkers a “double-edged sword” that will increasingly uncover Alzheimer’s pathology in people with no cognitive impairment. They warned of anxiety, depression and changes in self‑identity among individuals who may live for years—or decades—without symptoms, and for whom there is no proven way to prevent progression.

Disclosure protocols in research studies typically include pre‑test counseling, detailed consent forms and follow‑up visits. Commercial testing rarely offers that level of support.

There are also legal blind spots. The Genetic Information Nondiscrimination Act of 2008 bars health insurers and employers from discriminating based on the results of genetic tests, such as those that reveal Alzheimer’s‑linked APOE variants. It does not clearly cover protein biomarkers like p‑tau217, and it does not apply to life, disability or long‑term care insurance at all.

That means a middle‑aged person with a documented positive Alzheimer’s blood test could, in theory, face higher premiums or denials when shopping for long‑term care policies, depending on how insurers choose to treat such information and on state law.

Professional groups and regulators are only beginning to respond.

The Alzheimer’s Association has issued “appropriate use recommendations” urging clinicians to limit current blood biomarker tests to people with cognitive symptoms and to use them as part of a broader diagnostic workup, not in isolation. The group welcomed FDA’s clearance of Roche’s primary‑care test but stressed that blood tests should not replace thorough clinical evaluations.

The National Institute on Aging and the Alzheimer’s Association recently updated research criteria for Alzheimer’s to incorporate blood-based biomarkers into a biological staging system. At the same time, the guidelines caution that blood tests for treatment eligibility remain under validation and that PET scans and cerebrospinal fluid are still the reference standards.

For now, there is no national policy specifying who should be tested, when to disclose preclinical findings or how those findings should be documented in medical records.

In the exam room outside St. Louis, the 62-year‑old patient with memory complaints ultimately decided to proceed with the blood test. His result suggested Alzheimer’s‑type pathology was unlikely, and his doctor shifted the workup toward depression and sleep apnea.

His wife never got tested. For now, there was nothing to act on.

Similar decisions are beginning to play out in clinics across the country as Alzheimer’s blood tests arrive on front‑line lab menus.

Supporters say the tests will, over time, allow doctors to diagnose dementia earlier, get patients to treatment and support faster and spare many from invasive procedures. Skeptics point out that the drugs available today offer modest benefits, that test performance remains uneven, and that the health system has limited capacity to absorb a surge of newly labeled patients.

What is clear is that the technology has arrived before society has fully decided how much it wants to know about the future of its aging brains—and what should follow a simple tube of blood that comes back stamped “Alzheimer’s‑positive.”